PF-03716539

PF-03716539 is an orally administered small molecule drug developed by Pfizer and ViiV Healthcare for use as a pharmacokinetic enhancer of anti-infective drugs, particularly in the context of viral infections. Its primary mechanism is to inhibit Cytochrome P450 3A4 (CYP3A4), thereby potentially increasing the plasma concentrations of co-administered drugs metabolized by this enzyme. The compound has been evaluated in phase 1 clinical trials to assess its safety, tolerability, and drug-drug interaction potential with antiretroviral agents such as darunavir and maraviroc in healthy volunteers[1][2][3][4]. No further development beyond phase 1 has been reported.